author={V D Nefedov and Yu V Norseev and M A Toropova and Vladimir A Khalkin},
  journal={Russian Chemical Reviews},
  pages={87 - 98}
CONTENTS I. History of discovery 87 II. Isotopes of astatine 88 III. Astatine in nature 89 IV. Methods of obtaining and isolating astatine 89 V. Physical properties of astatine 90 VI. Chemical properties of astatine 91 VII. Astatine in organic compounds 95 VIII. Biological behaviour of astatine 96 

Measurement of the first ionization potential of astatine by laser ionization spectroscopy

The observed series of Rydberg states enabled the first determination of the ionization potential of the astatine atom, 9.31751(8) eV, which serves as a benchmark for quantum chemistry calculations of the properties of ast atine as well as for the theoretical prediction of the ionship potential of superheavy element 117.

A Solid-State Support for Separating Astatine-211 from Bismuth.

An extraction chromatographic processing method that simplifies 211At production in terms of purification and is excited about the potential of this procedure to address 211At supply and processing/purification problems.

Extraction of 211At from nitric acid solutions into various organic solvents for use as an α-source for radiation chemistry studies

Abstract The partitioning of 211At from an irradiated bismuth target using solvent extraction into several organic solvents is presented. Although astatine speciation is difficult to measure given

Development of an autonomous solvent extraction system to isolate astatine-211 from dissolved cyclotron bombarded bismuth targets

The development and optimization of the autonomous solvent extraction system is described, and the 211At yields from several ~1.1 GBq-level 211At processing runs are reported.

Radiochemical aspects of alpha emitting radionuclides for medical application

Abstract The use of α-emitting radionuclides in targeted alpha therapy (TAT) holds great potential for treatment of human diseases, such as cancer, due to the short pathlength and high potency of the

Absorbed dose simulation of meta-211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method, RAP

The present RAP dose conversion method could estimate 211 At-MABG absorbed doses from the pharmacokinetics of 131 I-MIBG with some limitations, and would be applicable to a large number of subjects for targeted nuclide therapy.

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.

A novel targeted therapy that combines the α-particle emitter astatine-211 (211At) and the anti-HER2 Nb 2Rs15d to selectively target HER2+ cancer cells is investigated and envisioned to be a promising therapeutic agent for TAT and aim toward efficacy evaluation.

Astatine Facing Janus: Halogen Bonding vs. Charge-Shift Bonding

Two antinomic characters, charge-shift bonding and halogen bonding, can result in weaker At-mediated interactions than their iodinated counterparts, which led to an unexpected finding in halogen bonds formed by C6At6.

68Ga- and 211At-Labeled RGD Peptides for Radiotheranostics with Multiradionuclides.

The usefulness of radiolabeled RGD peptide probes in radiotheranostics with multiradionuclides, such as a radiometal and a radiohalogen, and they could contribute to a personalized medicine regimen are indicated.